JPFOPHA@EC2606A

Fosun Pharmaceutical Obtained CSRC Approval for Issuing Sci-Tech Innovation Corporate Bonds

Fosun Pharma Granted Approval for Fumaining and Anlotinib Combined Phase II Clinical Trial for KRAS Mutated Lung Cancer

Fosun Pharmaceutical's Subsidiary Obtains Acceptance for Etomidate Hydrochloride Injection Drug Registration Application

Fosun Pharma's Subsidiary Hengruihansheng Granted Approval for Phase I Clinical Trial of HLX15 for Multiple Myeloma Treatment

Shanghai Henlius Licenses Lung Cancer Drug to Eisai for $155 Million

Fosun Pharmaceutical Subsidiary's Cyclophosphamide Injection Drug Registration Application Accepted by NMPA

F Hutchison and Eisai Sign License Agreement for Serplulimab

Fosun Pharma's Fumasilin® New Indication Drug Listing Application Accepted for Priority Review

Fosun Pharma Deputy Chairman Suggests Use of Health Insurance Data for Elderly Disease Innovation Drug R&D

Fosun Pharmaceutical to Hold Extraordinary General Meeting to Deliberate on Spin-off Listing Proposal

Fosun Pharmaceutical Completes RMB 1 Billion Innovative Technology Bond Issuance

Fosun Pharma's Subsidiary Secures Approval for Clinical Trial in Late-Stage Solid Tumor Treatment

Fosun Pharmaceutical's Subsidiary Obtains Approval for Drug Registration Application

Fosun Pharma's Subsidiary Hengenix Obtains NMPA Approval for HLX701 in Advanced Colorectal Cancer Clinical Trial

Fosun Pharma's Subsidiary Suzhou Er Ye Pharmaceuticals Receives Acceptance for Erythromycin Lactobionate for Injection Registration Application

Establishment of Zhonghui Fuhong Private Equity Investment Fund Partnership

Fosun Wanbang Resubmits Registration Application for R 潽瑞替尼 Capsules

Fosun Pharmaceutical's Subsidiary Kicks Off Phase I Clinical Trial for SRT-007 Prostate Cancer Radiopharmaceutical

Fosun Pharma Plans to Acquire Green Valley Pharmaceutical for 1.412 Billion to Integrate Innovative Drug Pipeline

Fosun Pharma Aims to Acquire 75% Equity of Green Valley Pharmaceutical for 1.412 Billion Yuan

CCOE

STARCOIN GROUP

ONEFORCE HLDGS

ROYAL DELUXE

STELUX HOLDINGS

TE HEALTHCARE

ASIAPAC FIN INV

WELIFE TECH

DRINDA

TIMELESS

520880

159506

02196

600196

08627

Fosun International Limited has filed a next-day disclosure return with HKEX, reporting the repurchase of 13,027,000 ordinary shares at a volume-weighted average price of HKD 3.7027 per share. The total consideration for the repurchase amounted to HKD 48,235,385, with individual share prices ranging from HKD 3.63 to HKD 3.80. This disclosure was made on February 27, 2026.

PUBT

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

FOSUN PHARMA

ORANGE TOUR

Fosun International files HKEX next-day disclosure return reporting 13,027,000-share repurchase at HKD 3.7027 per share

516930

512290

516610

588130

159992

159849

512010

159837

510660

516500

Shanghai Fosun Pharmaceutical receives regulatory approval for bond issuance

marketscreener

Minsheng Royal CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

E Fund CSI 300 Health Care ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC CSI All Share Health Care Devices ETF

SINOPHARM(CNCM LTD)

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI Biotechnology Theme ETF

Guotai SSE STAR Brand Name Drug ETF

China Universal 800 Health Care ETF

Shanghai Fosun Pharmaceutical receives regulatory approval for bond issuance

Fosun Pharma Gets Regulatory Nod for 6 Billion Yuan Bond Issue

Fosun Pharma Gets Regulatory Nod for 6 Billion Yuan Bond Issue

159316

Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China

Fosun Pharmaceutical Amends Drug Licensing Agreements

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Pharma

Fosun Pharmaceutical Amends Drug Licensing Agreements

Shanghai Fosun Pharma says NMPA accepts drug registration application of moxetomidate hydrochloride injection

Shanghai Fosun Pharma says NMPA accepts drug registration application of moxetomidate hydrochloride injection

Fosun Pharma Unit Gets China Acceptance for Anesthesia Drug Application

Fosun Pharma Unit Gets China Acceptance for Anesthesia Drug Application

Fosun Pharma Gets Regulatory Approval for Myeloma Drug Trial

Fosun Pharma Gets Regulatory Approval for Myeloma Drug Trial

Fosun Health Group plans to build its first overseas hospitals in Indonesia, aiming to expand amid China's push for global healthcare growth. CEO Frank Hu announced the initiative at a conference, highlighting Indonesia's large population and healthcare needs. While term sheets with local partners have been signed, formal contracts are pending. Fosun is also exploring local product distribution and manufacturing partnerships. The company, which operates 19 facilities in China, is targeting markets in South Asia, Southeast Asia, and the Middle East due to their economic growth and healthcare demands.

南华早报

Bosera Hang Seng Health Care ETF(QDII)

Fosun Health to build first overseas hospitals in Indonesia amid global push

159805

600576

516190

517770

512980

301025

00656

Fubo announced that it has reached a strategic cooperation with FOSUN WEALTH INTERNATIONAL HOLDING to independently incubate the AI-driven global one-stop wealth technology platform, Xinglu Technology, located in Hong Kong. Both parties will leverage their respective advantages to engage in deep cooperation in the area of overseas tokenization of real-world assets (RWA) related to cultural and creative intellectual property (IP), jointly exploring compliant innovation development paths and promoting the construction of an ecosystem that transforms cultural and creative IP into efficiently circulating digital assets

AASTOCKS

Penghua CSI Media ETF

Sunriver Culture Tourism

ChinaAMC CSI Cultural Entertainment Media ETF

AXA SPDB CSI Hugangshen Game and Culture Media ETF

GF Fund CSI Media ETF

DOOK

FOSUN INTL

Fubo Partners with Xinglu Technology to Expand Cultural and Creative IP Tokenization of Real-World Assets Overseas

China's industrial cybersecurity firm, Tiandi Hexing, has filed for a Hong Kong IPO, reporting a 20% revenue growth but continued losses. Established in 2007, the company is backed by major investors like Zijin Mining and Fosun. The demand for industrial cybersecurity is rising due to increasing cyberattacks, with the market projected to grow significantly. Tiandi Hexing leads the fragmented market with a 6.7% share, but still faces challenges, including a loss of 94.67 million yuan in the first nine months of 2025, despite high gross profit margins.

benzinga_article

China's Industrial Cybersecurity Firm Files For Hong Kong IPO - Key Investor Takeaways

JPFOPHA@EC2606A(23670.HK)

Fosun International files HKEX next-day disclosure return reporting 13,027,000-share repurchase at HKD 3.7027 per share

Shanghai Fosun Pharmaceutical receives regulatory approval for bond issuance

Fosun Pharma Gets Regulatory Nod for 6 Billion Yuan Bond Issue

Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China

Fosun Pharmaceutical Amends Drug Licensing Agreements